nodes	percent_of_prediction	percent_of_DWPC	metapath
Aclidinium—CHRM3—ureter—prostate cancer	0.0562	0.461	CbGeAlD
Aclidinium—CHRM5—epithelium—prostate cancer	0.00862	0.0707	CbGeAlD
Aclidinium—CHRM2—prostate gland—prostate cancer	0.00805	0.0661	CbGeAlD
Aclidinium—CHRM1—prostate gland—prostate cancer	0.00733	0.0601	CbGeAlD
Aclidinium—CHRM4—testis—prostate cancer	0.00661	0.0542	CbGeAlD
Aclidinium—CHRM3—prostate gland—prostate cancer	0.00656	0.0538	CbGeAlD
Aclidinium—BCHE—prostate gland—prostate cancer	0.00535	0.0439	CbGeAlD
Aclidinium—BCHE—seminal vesicle—prostate cancer	0.00453	0.0371	CbGeAlD
Aclidinium—CHRM3—renal system—prostate cancer	0.00447	0.0367	CbGeAlD
Aclidinium—CHRM3—urethra—prostate cancer	0.00439	0.036	CbGeAlD
Aclidinium—Infestation—Cabazitaxel—prostate cancer	0.00431	0.0074	CcSEcCtD
Aclidinium—Urinary tract disorder—Degarelix—prostate cancer	0.00405	0.00697	CcSEcCtD
Aclidinium—Eye disorder—Estradiol valerate/Dienogest—prostate cancer	0.00403	0.00693	CcSEcCtD
Aclidinium—Urethral disorder—Degarelix—prostate cancer	0.00402	0.00691	CcSEcCtD
Aclidinium—Eye disorder—Degarelix—prostate cancer	0.00383	0.00659	CcSEcCtD
Aclidinium—Diabetes mellitus—Goserelin—prostate cancer	0.00383	0.00659	CcSEcCtD
Aclidinium—Cough—Abiraterone—prostate cancer	0.00382	0.00656	CcSEcCtD
Aclidinium—Urinary tract disorder—Cabazitaxel—prostate cancer	0.00382	0.00656	CcSEcCtD
Aclidinium—Urethral disorder—Cabazitaxel—prostate cancer	0.00379	0.00651	CcSEcCtD
Aclidinium—Mediastinal disorder—Degarelix—prostate cancer	0.0037	0.00636	CcSEcCtD
Aclidinium—Eye disorder—Cabazitaxel—prostate cancer	0.00361	0.00621	CcSEcCtD
Aclidinium—Infection—Abiraterone—prostate cancer	0.00355	0.0061	CcSEcCtD
Aclidinium—Cough—Nilutamide—prostate cancer	0.00349	0.006	CcSEcCtD
Aclidinium—Mediastinal disorder—Cabazitaxel—prostate cancer	0.00348	0.00599	CcSEcCtD
Aclidinium—Sinusitis—Bicalutamide—prostate cancer	0.00346	0.00596	CcSEcCtD
Aclidinium—Cardiac failure—Goserelin—prostate cancer	0.00342	0.00587	CcSEcCtD
Aclidinium—Vision blurred—Degarelix—prostate cancer	0.00337	0.00579	CcSEcCtD
Aclidinium—Osteoarthritis—Goserelin—prostate cancer	0.00333	0.00573	CcSEcCtD
Aclidinium—Dry mouth—Nilutamide—prostate cancer	0.00333	0.00572	CcSEcCtD
Aclidinium—Rhinitis—Bicalutamide—prostate cancer	0.00332	0.00571	CcSEcCtD
Aclidinium—Urinary tract disorder—Bicalutamide—prostate cancer	0.00327	0.00563	CcSEcCtD
Aclidinium—Urethral disorder—Bicalutamide—prostate cancer	0.00325	0.00559	CcSEcCtD
Aclidinium—Urinary retention—Goserelin—prostate cancer	0.00317	0.00545	CcSEcCtD
Aclidinium—Infestation NOS—Ethinyl Estradiol—prostate cancer	0.00312	0.00537	CcSEcCtD
Aclidinium—Infestation—Ethinyl Estradiol—prostate cancer	0.00312	0.00537	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Abiraterone—prostate cancer	0.00308	0.0053	CcSEcCtD
Aclidinium—Nervous system disorder—Estradiol valerate/Dienogest—prostate cancer	0.00301	0.00517	CcSEcCtD
Aclidinium—Mediastinal disorder—Bicalutamide—prostate cancer	0.00299	0.00514	CcSEcCtD
Aclidinium—Dry mouth—Degarelix—prostate cancer	0.00297	0.00511	CcSEcCtD
Aclidinium—Cough—Cabazitaxel—prostate cancer	0.00294	0.00505	CcSEcCtD
Aclidinium—Sinusitis—Ethinyl Estradiol—prostate cancer	0.00293	0.00503	CcSEcCtD
Aclidinium—CHRM3—testis—prostate cancer	0.00289	0.0237	CbGeAlD
Aclidinium—Nervous system disorder—Degarelix—prostate cancer	0.00286	0.00491	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Nilutamide—prostate cancer	0.00282	0.00484	CcSEcCtD
Aclidinium—Rhinitis—Ethinyl Estradiol—prostate cancer	0.00281	0.00483	CcSEcCtD
Aclidinium—Dry mouth—Cabazitaxel—prostate cancer	0.0028	0.00482	CcSEcCtD
Aclidinium—Urinary tract disorder—Ethinyl Estradiol—prostate cancer	0.00277	0.00476	CcSEcCtD
Aclidinium—Dysphonia—Capecitabine—prostate cancer	0.00276	0.00474	CcSEcCtD
Aclidinium—BCHE—bone marrow—prostate cancer	0.00276	0.0226	CbGeAlD
Aclidinium—Urethral disorder—Ethinyl Estradiol—prostate cancer	0.00275	0.00472	CcSEcCtD
Aclidinium—Infection—Cabazitaxel—prostate cancer	0.00273	0.00469	CcSEcCtD
Aclidinium—Nervous system disorder—Cabazitaxel—prostate cancer	0.00269	0.00463	CcSEcCtD
Aclidinium—Tachycardia—Cabazitaxel—prostate cancer	0.00268	0.00461	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Estradiol valerate/Dienogest—prostate cancer	0.00265	0.00455	CcSEcCtD
Aclidinium—Osteoarthritis—Estradiol—prostate cancer	0.00264	0.00454	CcSEcCtD
Aclidinium—Eye disorder—Ethinyl Estradiol—prostate cancer	0.00262	0.0045	CcSEcCtD
Aclidinium—Infestation NOS—Conjugated Estrogens—prostate cancer	0.00254	0.00437	CcSEcCtD
Aclidinium—Infestation—Conjugated Estrogens—prostate cancer	0.00254	0.00437	CcSEcCtD
Aclidinium—Cardiac failure—Mitoxantrone—prostate cancer	0.00252	0.00434	CcSEcCtD
Aclidinium—Cough—Bicalutamide—prostate cancer	0.00252	0.00433	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Degarelix—prostate cancer	0.00252	0.00433	CcSEcCtD
Aclidinium—Diarrhoea—Estramustine—prostate cancer	0.00252	0.00433	CcSEcCtD
Aclidinium—Diarrhoea—Abiraterone—prostate cancer	0.00244	0.0042	CcSEcCtD
Aclidinium—Sinusitis—Goserelin—prostate cancer	0.00241	0.00414	CcSEcCtD
Aclidinium—Dry mouth—Bicalutamide—prostate cancer	0.0024	0.00413	CcSEcCtD
Aclidinium—Sinusitis—Conjugated Estrogens—prostate cancer	0.00239	0.0041	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Cabazitaxel—prostate cancer	0.00237	0.00408	CcSEcCtD
Aclidinium—Nasopharyngitis—Estradiol—prostate cancer	0.00236	0.00406	CcSEcCtD
Aclidinium—BCHE—testis—prostate cancer	0.00236	0.0193	CbGeAlD
Aclidinium—Infection—Bicalutamide—prostate cancer	0.00234	0.00402	CcSEcCtD
Aclidinium—Vomiting—Estramustine—prostate cancer	0.00234	0.00402	CcSEcCtD
Aclidinium—Rhinitis—Goserelin—prostate cancer	0.00231	0.00398	CcSEcCtD
Aclidinium—Nervous system disorder—Bicalutamide—prostate cancer	0.00231	0.00397	CcSEcCtD
Aclidinium—Headache—Estramustine—prostate cancer	0.0023	0.00396	CcSEcCtD
Aclidinium—Rhinitis—Conjugated Estrogens—prostate cancer	0.00229	0.00394	CcSEcCtD
Aclidinium—Urinary tract disorder—Goserelin—prostate cancer	0.00228	0.00392	CcSEcCtD
Aclidinium—Vomiting—Abiraterone—prostate cancer	0.00227	0.0039	CcSEcCtD
Aclidinium—Urethral disorder—Goserelin—prostate cancer	0.00226	0.00389	CcSEcCtD
Aclidinium—Vomiting—Estrone—prostate cancer	0.00223	0.00384	CcSEcCtD
Aclidinium—Diarrhoea—Nilutamide—prostate cancer	0.00223	0.00384	CcSEcCtD
Aclidinium—Diarrhoea—Flutamide—prostate cancer	0.00222	0.00382	CcSEcCtD
Aclidinium—Headache—Estrone—prostate cancer	0.0022	0.00378	CcSEcCtD
Aclidinium—Eye disorder—Goserelin—prostate cancer	0.00216	0.00371	CcSEcCtD
Aclidinium—Eye disorder—Conjugated Estrogens—prostate cancer	0.00213	0.00367	CcSEcCtD
Aclidinium—Cough—Ethinyl Estradiol—prostate cancer	0.00213	0.00366	CcSEcCtD
Aclidinium—Cardiac failure—Etoposide—prostate cancer	0.0021	0.00361	CcSEcCtD
Aclidinium—Vomiting—Nilutamide—prostate cancer	0.00207	0.00357	CcSEcCtD
Aclidinium—Vomiting—Flutamide—prostate cancer	0.00207	0.00355	CcSEcCtD
Aclidinium—Mediastinal disorder—Conjugated Estrogens—prostate cancer	0.00206	0.00354	CcSEcCtD
Aclidinium—Headache—Nilutamide—prostate cancer	0.00204	0.00351	CcSEcCtD
Aclidinium—Infestation NOS—Estradiol—prostate cancer	0.00204	0.0035	CcSEcCtD
Aclidinium—Infestation—Estradiol—prostate cancer	0.00204	0.0035	CcSEcCtD
Aclidinium—Headache—Flutamide—prostate cancer	0.00203	0.0035	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Bicalutamide—prostate cancer	0.00203	0.0035	CcSEcCtD
Aclidinium—Diarrhoea—Degarelix—prostate cancer	0.00199	0.00343	CcSEcCtD
Aclidinium—Infection—Ethinyl Estradiol—prostate cancer	0.00198	0.0034	CcSEcCtD
Aclidinium—Nervous system disorder—Ethinyl Estradiol—prostate cancer	0.00195	0.00336	CcSEcCtD
Aclidinium—Vomiting—Estradiol valerate/Dienogest—prostate cancer	0.00195	0.00335	CcSEcCtD
Aclidinium—Dysphonia—Epirubicin—prostate cancer	0.00192	0.00331	CcSEcCtD
Aclidinium—Headache—Estradiol valerate/Dienogest—prostate cancer	0.00192	0.0033	CcSEcCtD
Aclidinium—Sinusitis—Estradiol—prostate cancer	0.00191	0.00328	CcSEcCtD
Aclidinium—Diabetes mellitus—Capecitabine—prostate cancer	0.00189	0.00326	CcSEcCtD
Aclidinium—Vision blurred—Goserelin—prostate cancer	0.00189	0.00325	CcSEcCtD
Aclidinium—Diarrhoea—Cabazitaxel—prostate cancer	0.00188	0.00323	CcSEcCtD
Aclidinium—Vision blurred—Conjugated Estrogens—prostate cancer	0.00187	0.00322	CcSEcCtD
Aclidinium—Vomiting—Degarelix—prostate cancer	0.00185	0.00319	CcSEcCtD
Aclidinium—Rhinitis—Estradiol—prostate cancer	0.00183	0.00315	CcSEcCtD
Aclidinium—Headache—Degarelix—prostate cancer	0.00183	0.00314	CcSEcCtD
Aclidinium—Urinary tract disorder—Estradiol—prostate cancer	0.00181	0.0031	CcSEcCtD
Aclidinium—Urethral disorder—Estradiol—prostate cancer	0.00179	0.00308	CcSEcCtD
Aclidinium—Sinusitis—Mitoxantrone—prostate cancer	0.00178	0.00306	CcSEcCtD
Aclidinium—Dysphonia—Doxorubicin—prostate cancer	0.00178	0.00306	CcSEcCtD
Aclidinium—Cough—Goserelin—prostate cancer	0.00175	0.00301	CcSEcCtD
Aclidinium—Vomiting—Cabazitaxel—prostate cancer	0.00175	0.003	CcSEcCtD
Aclidinium—Cardiac failure—Docetaxel—prostate cancer	0.00174	0.003	CcSEcCtD
Aclidinium—Cough—Conjugated Estrogens—prostate cancer	0.00174	0.00298	CcSEcCtD
Aclidinium—Headache—Cabazitaxel—prostate cancer	0.00172	0.00296	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Ethinyl Estradiol—prostate cancer	0.00172	0.00296	CcSEcCtD
Aclidinium—BCHE—lymph node—prostate cancer	0.00171	0.014	CbGeAlD
Aclidinium—Eye disorder—Estradiol—prostate cancer	0.00171	0.00294	CcSEcCtD
Aclidinium—Rhinitis—Mitoxantrone—prostate cancer	0.00171	0.00294	CcSEcCtD
Aclidinium—Cardiac failure—Capecitabine—prostate cancer	0.00169	0.0029	CcSEcCtD
Aclidinium—Diabetes mellitus—Prednisone—prostate cancer	0.00169	0.0029	CcSEcCtD
Aclidinium—Dry mouth—Goserelin—prostate cancer	0.00167	0.00287	CcSEcCtD
Aclidinium—Osteoarthritis—Capecitabine—prostate cancer	0.00165	0.00283	CcSEcCtD
Aclidinium—Mediastinal disorder—Estradiol—prostate cancer	0.00165	0.00283	CcSEcCtD
Aclidinium—Infection—Goserelin—prostate cancer	0.00163	0.0028	CcSEcCtD
Aclidinium—Infection—Conjugated Estrogens—prostate cancer	0.00161	0.00277	CcSEcCtD
Aclidinium—Diarrhoea—Bicalutamide—prostate cancer	0.00161	0.00277	CcSEcCtD
Aclidinium—Nervous system disorder—Goserelin—prostate cancer	0.00161	0.00276	CcSEcCtD
Aclidinium—Tachycardia—Goserelin—prostate cancer	0.0016	0.00275	CcSEcCtD
Aclidinium—Nervous system disorder—Conjugated Estrogens—prostate cancer	0.00159	0.00274	CcSEcCtD
Aclidinium—Tachycardia—Conjugated Estrogens—prostate cancer	0.00158	0.00272	CcSEcCtD
Aclidinium—Infestation NOS—Etoposide—prostate cancer	0.00158	0.00271	CcSEcCtD
Aclidinium—Infestation—Etoposide—prostate cancer	0.00158	0.00271	CcSEcCtD
Aclidinium—Urinary retention—Capecitabine—prostate cancer	0.00157	0.00269	CcSEcCtD
Aclidinium—Nasopharyngitis—Docetaxel—prostate cancer	0.00152	0.00262	CcSEcCtD
Aclidinium—Cardiac failure—Prednisone—prostate cancer	0.0015	0.00259	CcSEcCtD
Aclidinium—Vomiting—Bicalutamide—prostate cancer	0.0015	0.00257	CcSEcCtD
Aclidinium—Headache—Bicalutamide—prostate cancer	0.00148	0.00254	CcSEcCtD
Aclidinium—Nasopharyngitis—Capecitabine—prostate cancer	0.00147	0.00253	CcSEcCtD
Aclidinium—Osteoarthritis—Prednisone—prostate cancer	0.00147	0.00252	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.0014	0.00241	CcSEcCtD
Aclidinium—Urinary tract disorder—Etoposide—prostate cancer	0.0014	0.00241	CcSEcCtD
Aclidinium—Vision blurred—Mitoxantrone—prostate cancer	0.0014	0.0024	CcSEcCtD
Aclidinium—Urethral disorder—Etoposide—prostate cancer	0.00139	0.00239	CcSEcCtD
Aclidinium—Cough—Estradiol—prostate cancer	0.00139	0.00239	CcSEcCtD
Aclidinium—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.00136	0.00234	CcSEcCtD
Aclidinium—Dry mouth—Estradiol—prostate cancer	0.00133	0.00228	CcSEcCtD
Aclidinium—Eye disorder—Etoposide—prostate cancer	0.00132	0.00228	CcSEcCtD
Aclidinium—Diabetes mellitus—Epirubicin—prostate cancer	0.00132	0.00227	CcSEcCtD
Aclidinium—Infestation NOS—Docetaxel—prostate cancer	0.00131	0.00226	CcSEcCtD
Aclidinium—Infestation—Docetaxel—prostate cancer	0.00131	0.00226	CcSEcCtD
Aclidinium—Cough—Mitoxantrone—prostate cancer	0.00129	0.00222	CcSEcCtD
Aclidinium—Infection—Estradiol—prostate cancer	0.00129	0.00222	CcSEcCtD
Aclidinium—Mediastinal disorder—Etoposide—prostate cancer	0.00128	0.0022	CcSEcCtD
Aclidinium—Nervous system disorder—Estradiol—prostate cancer	0.00127	0.00219	CcSEcCtD
Aclidinium—Infestation—Capecitabine—prostate cancer	0.00127	0.00218	CcSEcCtD
Aclidinium—Infestation NOS—Capecitabine—prostate cancer	0.00127	0.00218	CcSEcCtD
Aclidinium—Tachycardia—Estradiol—prostate cancer	0.00127	0.00218	CcSEcCtD
Aclidinium—Vomiting—Ethinyl Estradiol—prostate cancer	0.00127	0.00218	CcSEcCtD
Aclidinium—Headache—Ethinyl Estradiol—prostate cancer	0.00125	0.00214	CcSEcCtD
Aclidinium—Diabetes mellitus—Doxorubicin—prostate cancer	0.00122	0.0021	CcSEcCtD
Aclidinium—Infection—Mitoxantrone—prostate cancer	0.0012	0.00207	CcSEcCtD
Aclidinium—Tachycardia—Mitoxantrone—prostate cancer	0.00118	0.00203	CcSEcCtD
Aclidinium—Rhinitis—Docetaxel—prostate cancer	0.00118	0.00203	CcSEcCtD
Aclidinium—Cardiac failure—Epirubicin—prostate cancer	0.00118	0.00202	CcSEcCtD
Aclidinium—Urinary tract disorder—Docetaxel—prostate cancer	0.00116	0.002	CcSEcCtD
Aclidinium—Urethral disorder—Docetaxel—prostate cancer	0.00115	0.00198	CcSEcCtD
Aclidinium—Osteoarthritis—Epirubicin—prostate cancer	0.00115	0.00197	CcSEcCtD
Aclidinium—Rhinitis—Capecitabine—prostate cancer	0.00114	0.00197	CcSEcCtD
Aclidinium—Urinary tract disorder—Capecitabine—prostate cancer	0.00113	0.00194	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Estradiol—prostate cancer	0.00112	0.00193	CcSEcCtD
Aclidinium—Diarrhoea—Goserelin—prostate cancer	0.00112	0.00193	CcSEcCtD
Aclidinium—Urethral disorder—Capecitabine—prostate cancer	0.00112	0.00192	CcSEcCtD
Aclidinium—Diarrhoea—Conjugated Estrogens—prostate cancer	0.00111	0.00191	CcSEcCtD
Aclidinium—Eye disorder—Docetaxel—prostate cancer	0.0011	0.00189	CcSEcCtD
Aclidinium—Cardiac failure—Doxorubicin—prostate cancer	0.00109	0.00187	CcSEcCtD
Aclidinium—Cough—Etoposide—prostate cancer	0.00108	0.00185	CcSEcCtD
Aclidinium—Eye disorder—Capecitabine—prostate cancer	0.00107	0.00183	CcSEcCtD
Aclidinium—Osteoarthritis—Doxorubicin—prostate cancer	0.00106	0.00183	CcSEcCtD
Aclidinium—Mediastinal disorder—Docetaxel—prostate cancer	0.00106	0.00182	CcSEcCtD
Aclidinium—Vomiting—Goserelin—prostate cancer	0.00104	0.00179	CcSEcCtD
Aclidinium—Vomiting—Conjugated Estrogens—prostate cancer	0.00103	0.00177	CcSEcCtD
Aclidinium—Mediastinal disorder—Capecitabine—prostate cancer	0.00103	0.00177	CcSEcCtD
Aclidinium—Nasopharyngitis—Epirubicin—prostate cancer	0.00103	0.00177	CcSEcCtD
Aclidinium—Headache—Goserelin—prostate cancer	0.00103	0.00176	CcSEcCtD
Aclidinium—Headache—Conjugated Estrogens—prostate cancer	0.00102	0.00175	CcSEcCtD
Aclidinium—Infection—Etoposide—prostate cancer	0.001	0.00172	CcSEcCtD
Aclidinium—Tachycardia—Etoposide—prostate cancer	0.000983	0.00169	CcSEcCtD
Aclidinium—Nasopharyngitis—Doxorubicin—prostate cancer	0.00095	0.00163	CcSEcCtD
Aclidinium—Eye disorder—Prednisone—prostate cancer	0.000949	0.00163	CcSEcCtD
Aclidinium—Vision blurred—Capecitabine—prostate cancer	0.000935	0.00161	CcSEcCtD
Aclidinium—Cough—Docetaxel—prostate cancer	0.000895	0.00154	CcSEcCtD
Aclidinium—Diarrhoea—Estradiol—prostate cancer	0.000889	0.00153	CcSEcCtD
Aclidinium—Infestation NOS—Epirubicin—prostate cancer	0.000885	0.00152	CcSEcCtD
Aclidinium—Infestation—Epirubicin—prostate cancer	0.000885	0.00152	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Etoposide—prostate cancer	0.000869	0.00149	CcSEcCtD
Aclidinium—Cough—Capecitabine—prostate cancer	0.000866	0.00149	CcSEcCtD
Aclidinium—Dry mouth—Docetaxel—prostate cancer	0.000854	0.00147	CcSEcCtD
Aclidinium—Vision blurred—Prednisone—prostate cancer	0.000833	0.00143	CcSEcCtD
Aclidinium—Infection—Docetaxel—prostate cancer	0.000831	0.00143	CcSEcCtD
Aclidinium—Sinusitis—Epirubicin—prostate cancer	0.00083	0.00143	CcSEcCtD
Aclidinium—Diarrhoea—Mitoxantrone—prostate cancer	0.000828	0.00142	CcSEcCtD
Aclidinium—Dry mouth—Capecitabine—prostate cancer	0.000826	0.00142	CcSEcCtD
Aclidinium—Vomiting—Estradiol—prostate cancer	0.000826	0.00142	CcSEcCtD
Aclidinium—Nervous system disorder—Docetaxel—prostate cancer	0.000821	0.00141	CcSEcCtD
Aclidinium—Infestation NOS—Doxorubicin—prostate cancer	0.000819	0.00141	CcSEcCtD
Aclidinium—Infestation—Doxorubicin—prostate cancer	0.000819	0.00141	CcSEcCtD
Aclidinium—Tachycardia—Docetaxel—prostate cancer	0.000817	0.0014	CcSEcCtD
Aclidinium—Headache—Estradiol—prostate cancer	0.000814	0.0014	CcSEcCtD
Aclidinium—Infection—Capecitabine—prostate cancer	0.000805	0.00138	CcSEcCtD
Aclidinium—Rhinitis—Epirubicin—prostate cancer	0.000796	0.00137	CcSEcCtD
Aclidinium—Nervous system disorder—Capecitabine—prostate cancer	0.000794	0.00137	CcSEcCtD
Aclidinium—Tachycardia—Capecitabine—prostate cancer	0.000791	0.00136	CcSEcCtD
Aclidinium—Urinary tract disorder—Epirubicin—prostate cancer	0.000784	0.00135	CcSEcCtD
Aclidinium—Urethral disorder—Epirubicin—prostate cancer	0.000779	0.00134	CcSEcCtD
Aclidinium—Vomiting—Mitoxantrone—prostate cancer	0.00077	0.00132	CcSEcCtD
Aclidinium—Sinusitis—Doxorubicin—prostate cancer	0.000768	0.00132	CcSEcCtD
Aclidinium—Headache—Mitoxantrone—prostate cancer	0.000758	0.0013	CcSEcCtD
Aclidinium—Eye disorder—Epirubicin—prostate cancer	0.000742	0.00128	CcSEcCtD
Aclidinium—Rhinitis—Doxorubicin—prostate cancer	0.000737	0.00127	CcSEcCtD
Aclidinium—Urinary tract disorder—Doxorubicin—prostate cancer	0.000726	0.00125	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000722	0.00124	CcSEcCtD
Aclidinium—Urethral disorder—Doxorubicin—prostate cancer	0.00072	0.00124	CcSEcCtD
Aclidinium—Infection—Prednisone—prostate cancer	0.000717	0.00123	CcSEcCtD
Aclidinium—Mediastinal disorder—Epirubicin—prostate cancer	0.000716	0.00123	CcSEcCtD
Aclidinium—Nervous system disorder—Prednisone—prostate cancer	0.000708	0.00122	CcSEcCtD
Aclidinium—Tachycardia—Prednisone—prostate cancer	0.000704	0.00121	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000699	0.0012	CcSEcCtD
Aclidinium—Diarrhoea—Etoposide—prostate cancer	0.000689	0.00118	CcSEcCtD
Aclidinium—Eye disorder—Doxorubicin—prostate cancer	0.000687	0.00118	CcSEcCtD
Aclidinium—Mediastinal disorder—Doxorubicin—prostate cancer	0.000662	0.00114	CcSEcCtD
Aclidinium—Vision blurred—Epirubicin—prostate cancer	0.000652	0.00112	CcSEcCtD
Aclidinium—Vomiting—Etoposide—prostate cancer	0.00064	0.0011	CcSEcCtD
Aclidinium—Headache—Etoposide—prostate cancer	0.000631	0.00108	CcSEcCtD
Aclidinium—Cough—Epirubicin—prostate cancer	0.000603	0.00104	CcSEcCtD
Aclidinium—Vision blurred—Doxorubicin—prostate cancer	0.000603	0.00104	CcSEcCtD
Aclidinium—Dry mouth—Epirubicin—prostate cancer	0.000576	0.00099	CcSEcCtD
Aclidinium—Diarrhoea—Docetaxel—prostate cancer	0.000572	0.000984	CcSEcCtD
Aclidinium—Infection—Epirubicin—prostate cancer	0.000561	0.000964	CcSEcCtD
Aclidinium—Cough—Doxorubicin—prostate cancer	0.000558	0.00096	CcSEcCtD
Aclidinium—Diarrhoea—Capecitabine—prostate cancer	0.000554	0.000953	CcSEcCtD
Aclidinium—Nervous system disorder—Epirubicin—prostate cancer	0.000553	0.000951	CcSEcCtD
Aclidinium—Tachycardia—Epirubicin—prostate cancer	0.000551	0.000947	CcSEcCtD
Aclidinium—Dry mouth—Doxorubicin—prostate cancer	0.000533	0.000916	CcSEcCtD
Aclidinium—Vomiting—Docetaxel—prostate cancer	0.000532	0.000915	CcSEcCtD
Aclidinium—Headache—Docetaxel—prostate cancer	0.000524	0.000901	CcSEcCtD
Aclidinium—Infection—Doxorubicin—prostate cancer	0.000519	0.000892	CcSEcCtD
Aclidinium—Vomiting—Capecitabine—prostate cancer	0.000515	0.000885	CcSEcCtD
Aclidinium—Nervous system disorder—Doxorubicin—prostate cancer	0.000512	0.00088	CcSEcCtD
Aclidinium—Tachycardia—Doxorubicin—prostate cancer	0.00051	0.000876	CcSEcCtD
Aclidinium—Headache—Capecitabine—prostate cancer	0.000507	0.000872	CcSEcCtD
Aclidinium—Diarrhoea—Prednisone—prostate cancer	0.000494	0.000849	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000487	0.000838	CcSEcCtD
Aclidinium—Vomiting—Prednisone—prostate cancer	0.000459	0.000789	CcSEcCtD
Aclidinium—Headache—Prednisone—prostate cancer	0.000452	0.000777	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000451	0.000775	CcSEcCtD
Aclidinium—Diarrhoea—Epirubicin—prostate cancer	0.000386	0.000664	CcSEcCtD
Aclidinium—Vomiting—Epirubicin—prostate cancer	0.000359	0.000617	CcSEcCtD
Aclidinium—Diarrhoea—Doxorubicin—prostate cancer	0.000357	0.000614	CcSEcCtD
Aclidinium—Headache—Epirubicin—prostate cancer	0.000354	0.000608	CcSEcCtD
Aclidinium—Vomiting—Doxorubicin—prostate cancer	0.000332	0.000571	CcSEcCtD
Aclidinium—Headache—Doxorubicin—prostate cancer	0.000327	0.000562	CcSEcCtD
Aclidinium—CHRM4—Signaling Pathways—FGF2—prostate cancer	2.76e-05	9.31e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—CXCL8—prostate cancer	2.76e-05	9.3e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—CXCL8—prostate cancer	2.75e-05	9.27e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—ERBB3—prostate cancer	2.74e-05	9.24e-05	CbGpPWpGaD
Aclidinium—CHRM5—GPCR downstream signaling—PIK3CA—prostate cancer	2.74e-05	9.23e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—FGFR2—prostate cancer	2.73e-05	9.23e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—SERPINE1—prostate cancer	2.73e-05	9.21e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—ERBB3—prostate cancer	2.73e-05	9.21e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—FGFR2—prostate cancer	2.73e-05	9.2e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—NOS3—prostate cancer	2.72e-05	9.19e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—CXCL8—prostate cancer	2.72e-05	9.18e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—ERBB3—prostate cancer	2.7e-05	9.12e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—KRAS—prostate cancer	2.7e-05	9.12e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—FGFR2—prostate cancer	2.7e-05	9.11e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—JAK2—prostate cancer	2.65e-05	8.93e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—FGF2—prostate cancer	2.64e-05	8.92e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PIK3CG—prostate cancer	2.64e-05	8.9e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—IL2—prostate cancer	2.63e-05	8.89e-05	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—PIK3CB—prostate cancer	2.63e-05	8.86e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—IL2—prostate cancer	2.63e-05	8.86e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—TERT—prostate cancer	2.63e-05	8.86e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—TERT—prostate cancer	2.62e-05	8.83e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—NOS3—prostate cancer	2.61e-05	8.8e-05	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—PTGS2—prostate cancer	2.6e-05	8.78e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—IL2—prostate cancer	2.6e-05	8.77e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—PIK3CA—prostate cancer	2.59e-05	8.75e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—TERT—prostate cancer	2.59e-05	8.74e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—MDM2—prostate cancer	2.58e-05	8.72e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—ERBB2—prostate cancer	2.55e-05	8.59e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—JAK2—prostate cancer	2.53e-05	8.55e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—PIK3CB—prostate cancer	2.51e-05	8.48e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—HIF1A—prostate cancer	2.51e-05	8.47e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—HIF1A—prostate cancer	2.5e-05	8.44e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—INS—prostate cancer	2.5e-05	8.42e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—PIK3CA—prostate cancer	2.48e-05	8.38e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—HIF1A—prostate cancer	2.48e-05	8.36e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MDM2—prostate cancer	2.47e-05	8.35e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—LEP—prostate cancer	2.45e-05	8.27e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—CREBBP—prostate cancer	2.44e-05	8.25e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—LEP—prostate cancer	2.44e-05	8.24e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—ERBB2—prostate cancer	2.44e-05	8.23e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CAV1—prostate cancer	2.43e-05	8.19e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CAV1—prostate cancer	2.42e-05	8.17e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—LEP—prostate cancer	2.42e-05	8.16e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CXCL8—prostate cancer	2.42e-05	8.15e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—PIK3CB—prostate cancer	2.41e-05	8.12e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—KDR—prostate cancer	2.4e-05	8.1e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CAV1—prostate cancer	2.4e-05	8.09e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—KDR—prostate cancer	2.39e-05	8.07e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—KDR—prostate cancer	2.37e-05	8e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CDKN1B—prostate cancer	2.36e-05	7.96e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—ESR1—prostate cancer	2.34e-05	7.89e-05	CbGpPWpGaD
Aclidinium—CHRM4—GPCR downstream signaling—AKT1—prostate cancer	2.33e-05	7.87e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—ESR1—prostate cancer	2.33e-05	7.87e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PIK3CD—prostate cancer	2.32e-05	7.82e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CXCL8—prostate cancer	2.31e-05	7.8e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CASP3—prostate cancer	2.31e-05	7.8e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—ESR1—prostate cancer	2.31e-05	7.79e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—IL2—prostate cancer	2.31e-05	7.79e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—IL6—prostate cancer	2.3e-05	7.75e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—BAD—prostate cancer	2.28e-05	7.7e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—BAD—prostate cancer	2.28e-05	7.68e-05	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—PTEN—prostate cancer	2.27e-05	7.66e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CDKN1B—prostate cancer	2.26e-05	7.62e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—BAD—prostate cancer	2.25e-05	7.61e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CCND1—prostate cancer	2.25e-05	7.59e-05	CbGpPWpGaD
Aclidinium—CHRM5—GPCR downstream signaling—AKT1—prostate cancer	2.23e-05	7.54e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CTNNB1—prostate cancer	2.23e-05	7.52e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CASP3—prostate cancer	2.21e-05	7.47e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PIK3CG—prostate cancer	2.21e-05	7.46e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—APC—prostate cancer	2.21e-05	7.46e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—IL2—prostate cancer	2.21e-05	7.46e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PIK3CG—prostate cancer	2.2e-05	7.44e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—APC—prostate cancer	2.2e-05	7.44e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—IL6—prostate cancer	2.2e-05	7.42e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—NOS3—prostate cancer	2.19e-05	7.38e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—IRS1—prostate cancer	2.19e-05	7.38e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—EGF—prostate cancer	2.19e-05	7.38e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—MMP9—prostate cancer	2.18e-05	7.37e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—APC—prostate cancer	2.18e-05	7.37e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PIK3CG—prostate cancer	2.18e-05	7.37e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—EGF—prostate cancer	2.18e-05	7.35e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—IRS1—prostate cancer	2.18e-05	7.35e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CDKN1A—prostate cancer	2.18e-05	7.34e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—PTEN—prostate cancer	2.17e-05	7.33e-05	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—EP300—prostate cancer	2.17e-05	7.3e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—EGF—prostate cancer	2.16e-05	7.28e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—IRS1—prostate cancer	2.16e-05	7.28e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CCND1—prostate cancer	2.15e-05	7.27e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CTNNB1—prostate cancer	2.13e-05	7.2e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—GSK3B—prostate cancer	2.12e-05	7.16e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—AKT1—prostate cancer	2.12e-05	7.15e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—GSK3B—prostate cancer	2.12e-05	7.14e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—GSK3B—prostate cancer	2.1e-05	7.07e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—INS—prostate cancer	2.09e-05	7.06e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MMP9—prostate cancer	2.09e-05	7.06e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—INS—prostate cancer	2.09e-05	7.04e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CDKN1A—prostate cancer	2.08e-05	7.03e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—PTEN—prostate cancer	2.08e-05	7.02e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—EP300—prostate cancer	2.07e-05	6.99e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—INS—prostate cancer	2.07e-05	6.97e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CREBBP—prostate cancer	2.05e-05	6.92e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CREBBP—prostate cancer	2.04e-05	6.9e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—AKT1—prostate cancer	2.03e-05	6.85e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—IGF1—prostate cancer	2.03e-05	6.83e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CREBBP—prostate cancer	2.02e-05	6.83e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PIK3CB—prostate cancer	2.02e-05	6.82e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—IGF1—prostate cancer	2.02e-05	6.81e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—EGFR—prostate cancer	2.02e-05	6.8e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—SRC—prostate cancer	2.01e-05	6.79e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—EGFR—prostate cancer	2.01e-05	6.78e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PTGS2—prostate cancer	2e-05	6.75e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—IGF1—prostate cancer	2e-05	6.74e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—EGFR—prostate cancer	1.99e-05	6.71e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—EP300—prostate cancer	1.98e-05	6.69e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—VEGFA—prostate cancer	1.96e-05	6.62e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MAP2K1—prostate cancer	1.96e-05	6.6e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MAP2K1—prostate cancer	1.95e-05	6.58e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PIK3CD—prostate cancer	1.94e-05	6.56e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—STAT3—prostate cancer	1.94e-05	6.55e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PIK3CD—prostate cancer	1.94e-05	6.54e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MAP2K1—prostate cancer	1.93e-05	6.52e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—SRC—prostate cancer	1.93e-05	6.51e-05	CbGpPWpGaD
Aclidinium—CHRM1—GPCR downstream signaling—PIK3CA—prostate cancer	1.93e-05	6.5e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—SERPINE1—prostate cancer	1.92e-05	6.49e-05	CbGpPWpGaD
Aclidinium—CHRM3—GPCR downstream signaling—PIK3CA—prostate cancer	1.92e-05	6.48e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PIK3CD—prostate cancer	1.92e-05	6.48e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—SERPINE1—prostate cancer	1.92e-05	6.47e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—KRAS—prostate cancer	1.9e-05	6.42e-05	CbGpPWpGaD
Aclidinium—CHRM2—GPCR downstream signaling—PIK3CA—prostate cancer	1.9e-05	6.41e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—SERPINE1—prostate cancer	1.9e-05	6.4e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—KRAS—prostate cancer	1.9e-05	6.4e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—KRAS—prostate cancer	1.88e-05	6.34e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—VEGFA—prostate cancer	1.88e-05	6.34e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—FGF2—prostate cancer	1.86e-05	6.28e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—STAT3—prostate cancer	1.86e-05	6.28e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—FGF2—prostate cancer	1.86e-05	6.26e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—FGF2—prostate cancer	1.84e-05	6.2e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—NOS3—prostate cancer	1.84e-05	6.19e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—NOS3—prostate cancer	1.83e-05	6.17e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—NOS3—prostate cancer	1.81e-05	6.11e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—MYC—prostate cancer	1.8e-05	6.09e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—TGFB1—prostate cancer	1.8e-05	6.07e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—JAK2—prostate cancer	1.78e-05	6.02e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—JAK2—prostate cancer	1.78e-05	6e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—EGFR—prostate cancer	1.77e-05	5.96e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—JAK2—prostate cancer	1.76e-05	5.94e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—PIK3CA—prostate cancer	1.75e-05	5.9e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PTEN—prostate cancer	1.75e-05	5.89e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—PIK3CA—prostate cancer	1.74e-05	5.88e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MDM2—prostate cancer	1.74e-05	5.88e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MDM2—prostate cancer	1.74e-05	5.86e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MYC—prostate cancer	1.73e-05	5.83e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—PIK3CA—prostate cancer	1.73e-05	5.82e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—TGFB1—prostate cancer	1.72e-05	5.82e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MDM2—prostate cancer	1.72e-05	5.8e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—ERBB2—prostate cancer	1.72e-05	5.79e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—ERBB2—prostate cancer	1.71e-05	5.78e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—ERBB2—prostate cancer	1.7e-05	5.72e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PIK3CB—prostate cancer	1.69e-05	5.72e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—EGFR—prostate cancer	1.69e-05	5.7e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PIK3CB—prostate cancer	1.69e-05	5.7e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PIK3CB—prostate cancer	1.67e-05	5.64e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—KRAS—prostate cancer	1.67e-05	5.63e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—EP300—prostate cancer	1.66e-05	5.62e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CXCL8—prostate cancer	1.63e-05	5.49e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CXCL8—prostate cancer	1.62e-05	5.48e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CXCL8—prostate cancer	1.61e-05	5.42e-05	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—PIK3CA—prostate cancer	1.6e-05	5.4e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—KRAS—prostate cancer	1.6e-05	5.39e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CDKN1B—prostate cancer	1.59e-05	5.37e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CDKN1B—prostate cancer	1.59e-05	5.35e-05	CbGpPWpGaD
Aclidinium—CHRM1—GPCR downstream signaling—AKT1—prostate cancer	1.57e-05	5.31e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CDKN1B—prostate cancer	1.57e-05	5.3e-05	CbGpPWpGaD
Aclidinium—CHRM3—GPCR downstream signaling—AKT1—prostate cancer	1.57e-05	5.29e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CASP3—prostate cancer	1.56e-05	5.26e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—IL2—prostate cancer	1.56e-05	5.25e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CASP3—prostate cancer	1.55e-05	5.24e-05	CbGpPWpGaD
Aclidinium—CHRM2—GPCR downstream signaling—AKT1—prostate cancer	1.55e-05	5.24e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—IL2—prostate cancer	1.55e-05	5.23e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—IL6—prostate cancer	1.55e-05	5.22e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—IL6—prostate cancer	1.54e-05	5.21e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CASP3—prostate cancer	1.54e-05	5.19e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—IL2—prostate cancer	1.54e-05	5.18e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—PIK3CA—prostate cancer	1.53e-05	5.17e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—IL6—prostate cancer	1.53e-05	5.16e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CCND1—prostate cancer	1.52e-05	5.12e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CCND1—prostate cancer	1.51e-05	5.1e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CTNNB1—prostate cancer	1.5e-05	5.07e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CCND1—prostate cancer	1.5e-05	5.05e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CTNNB1—prostate cancer	1.5e-05	5.05e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CTNNB1—prostate cancer	1.48e-05	5e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—TP53—prostate cancer	1.48e-05	5e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MMP9—prostate cancer	1.47e-05	4.97e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MMP9—prostate cancer	1.47e-05	4.95e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CDKN1A—prostate cancer	1.47e-05	4.95e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—PIK3CA—prostate cancer	1.47e-05	4.95e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PTEN—prostate cancer	1.46e-05	4.94e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CDKN1A—prostate cancer	1.46e-05	4.94e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PTEN—prostate cancer	1.46e-05	4.92e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MMP9—prostate cancer	1.45e-05	4.91e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	1.45e-05	4.89e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PTEN—prostate cancer	1.45e-05	4.88e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—AKT1—prostate cancer	1.43e-05	4.82e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—AKT1—prostate cancer	1.42e-05	4.8e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—TP53—prostate cancer	1.42e-05	4.79e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—AKT1—prostate cancer	1.41e-05	4.76e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—EP300—prostate cancer	1.4e-05	4.71e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—EP300—prostate cancer	1.39e-05	4.7e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—EP300—prostate cancer	1.38e-05	4.65e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—SRC—prostate cancer	1.36e-05	4.58e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—IL6—prostate cancer	1.36e-05	4.58e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—SRC—prostate cancer	1.35e-05	4.57e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—SRC—prostate cancer	1.34e-05	4.52e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—VEGFA—prostate cancer	1.32e-05	4.46e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—VEGFA—prostate cancer	1.32e-05	4.45e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—STAT3—prostate cancer	1.31e-05	4.42e-05	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—AKT1—prostate cancer	1.31e-05	4.41e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—VEGFA—prostate cancer	1.31e-05	4.4e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—STAT3—prostate cancer	1.31e-05	4.4e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—IL6—prostate cancer	1.3e-05	4.38e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—STAT3—prostate cancer	1.29e-05	4.36e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—AKT1—prostate cancer	1.25e-05	4.22e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PIK3CA—prostate cancer	1.23e-05	4.15e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MYC—prostate cancer	1.22e-05	4.11e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—TGFB1—prostate cancer	1.21e-05	4.1e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MYC—prostate cancer	1.21e-05	4.09e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—TGFB1—prostate cancer	1.21e-05	4.08e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MYC—prostate cancer	1.2e-05	4.05e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—AKT1—prostate cancer	1.2e-05	4.04e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—TGFB1—prostate cancer	1.2e-05	4.04e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—EGFR—prostate cancer	1.19e-05	4.02e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—EGFR—prostate cancer	1.19e-05	4e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—EGFR—prostate cancer	1.18e-05	3.96e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—KRAS—prostate cancer	1.12e-05	3.79e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—KRAS—prostate cancer	1.12e-05	3.78e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—KRAS—prostate cancer	1.11e-05	3.74e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	1.03e-05	3.49e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PIK3CA—prostate cancer	1.03e-05	3.47e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	1.02e-05	3.44e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—AKT1—prostate cancer	1.01e-05	3.39e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—TP53—prostate cancer	9.99e-06	3.37e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—TP53—prostate cancer	9.96e-06	3.36e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—TP53—prostate cancer	9.87e-06	3.33e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—IL6—prostate cancer	9.15e-06	3.09e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—IL6—prostate cancer	9.12e-06	3.08e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—IL6—prostate cancer	9.03e-06	3.05e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—AKT1—prostate cancer	8.44e-06	2.85e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—AKT1—prostate cancer	8.41e-06	2.84e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—AKT1—prostate cancer	8.33e-06	2.81e-05	CbGpPWpGaD
